勃林格殷格翰的思力华中国上市了吗？

(Repimat) is a specific and selective anticholinergic drug that is commonly used in the clinical treatment of chronic obstructive pulmonary disease. The main ingredient of this drug is tiotropium bromide, which has an affinity similar to the muscarinic receptor subtypes M1-M5. It can bind to the M3 receptor on smooth muscle to relax the smooth muscle to achieve the purpose of dilating the bronchus. It can also reduce the airway inflammatory response of the bronchus and delay the further development of lung function. So, has Boehringer Ingelheim’s Slivar been launched in China?

Siliva was launched globally in 2002, and in 2006 it was launched in China. In 2007, Siliva devices were launched globally. In these listed countries and regions, patients can buy Spiriva from Boehringer Ingelheim of Germany. For domestic patients, they can also enjoy the discounts brought by medical insurance when purchasing medicines in major domestic hospitals and pharmacies. However, despite this, many patients with poor family finances still cannot afford the costs of long-term treatment. In this regard, patients can purchase medicines overseas through Medical Companion Travel, where they can buy more cost-effective Silivar.

In order to allow patients to receive and benefit from the treatment of Siliva, Boehringer Ingelheim continues to develop new products and try various product combinations. At present, the main drugs sold in my country are Silivar, Aitrole, and Cobite (mainly used to treat chronic obstructive pulmonary disease), Muscotan (mainly used to protect the lungs and can eliminate phlegm), Senfuluo (mainly used to treat Parkinson's disease), Mecasol, Mejisol (mainly used to treat hypertension), Aitongli (mainly used to treat acute myocardial infarction and ischemic stroke), and Mobico (can relieve inflammation and pain).

In addition to the above products, there are also diabetes, anti-tumor and atrial fibrillation stroke prevention products that will be launched soon, making Boehringer Ingelheim’s product line in China richer and more diversified. It can be seen that the products launched in China by the affiliated company Boehringer Ingelheim cover a variety of treatment areas, such as central nervous system diseases, metabolic diseases, cardiovascular diseases, immunity and inflammation, etc.

Recommended hot articles: /newsDetail/94288.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.